Indication
For treatment of adult patients with locally advanced, unresectable NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum‑based chemoradiation therapy.
Medicine details
- Medicine name:
- osimertinib (Tagrisso)
- SMC ID:
- SMC2815
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 13 April 2026
- SMC meeting date:
- TBC
- Patient group submission deadline:
- 02 February 2026